NEJM/X
Oct 1, 2025, 15:39
Boosting Stroke Thrombolysis․ Tirofiban Shows Promise in ASSET-IT Trial
The New England Journal of Medicine (NEJM), has shared a post on X:
“ASSET-IT phase 3 trial. Guidelines recommend intravenous thrombolysis within 4.5 hours after onset of acute ischemic stroke, but vascular reocclusion may occur.
Adjunct treatment with tirofiban might improve outcomes. Research findings are summarized in a new Quick Take video.”
Read more here.
Stay updated with Hemostasis Today.
-
Apr 16, 2026, 03:36Santagata Davide: Atypical Vascular Events Revealing Underlying Clonal Autoinflammation
-
Apr 16, 2026, 03:35Iron Deficiency in Women During Reproductive Years – ASH
-
Apr 16, 2026, 03:33Abdallah Othman: Overview of Coronary Arterial Anatomy and Its Clinical Implications
-
Apr 16, 2026, 03:14Laura Girardi: A Survey Study on the Management of Incidental Pulmonary Embolism in Patients with Cancer
-
Apr 16, 2026, 03:10Folusho Adeosun: Your 30-Minute Plan for SCD Emergencies
-
Apr 16, 2026, 02:57Charlie Windri: CAC as the Missing Link in Lp(a) Risk
-
Apr 15, 2026, 21:27Satish Bondala: Blood Bank and Transfusion Services – The Lifeline of Hospitals
-
Apr 15, 2026, 21:26Tareq Abadl: Understanding Thalassemia – Breaking the ‘Ordinary Anemia’ Myth
-
Apr 15, 2026, 21:24Wolfgang Miesbach: Key Message from John Semple on Platelets as Immune Cells in ITP